Intelligence / Healthtech / New Clinical Trials / GRIN Therapeutics, Inc.
GRIN Therapeutics, Inc.
17 Nov 2026: Trial registered · A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 17 Nov 2026
- Title
- A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants
- Conditions
- GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07941206
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at GRIN Therapeutics, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for GRIN Therapeutics, Inc. in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.